Abbvie’s Revenue by Region (2013-2022)

This statistic highlights Abbvie’s Revenue by Region on a yearly basis from 2013 onwards, split between Brazil, Canada, China, France, Germany, Italy, Japan, Spain, The Netherlands, United Kingdom, United States and Other countries.

Abbvie Inc is an American biopharmaceutical company. The company uses its expertise, dedicated personnel and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.

Abbvie’s Revenue by Region

(All figures in billions, except percentages)

Abbvie’s total revenue has increased from $33.27 billion in FY 2019 to $45.80 billion in FY 2020, which is a 38% increase. The reason for this increase is due to the rise in demand for immunology medicines such as Skyrizi and Rinvoq during the Covid-19 pandemic.

An analysis of the region-wise revenue of the company is discussed below.

• United States: A majority of Abbvie’s revenue comes from the United States, which contributed about 76% of total revenue in FY 2020 amounting to $34.88 billion. There was a 46% increase in revenue compared to FY 2019 where the revenue generated was $23.91 billion.
• Other countries: This region was the second biggest market for Abbvie Inc. during FY 2020 as it contributed about 9% of the company’s total revenue. There was a 0.25 % fall in the company’s revenue in FY 2020 to $3.98 billion, from $3.99 billion in FY 2019.
• Germany: During FY 2020, Germany contributed about 1% of the company’s total revenue. There was a decrease in the company’s revenue from this region, from $0.91 billion in FY 2019 to $0.79 billion in FY 2020.
• Canada: The Canadian region contributed only about 1% of the total revenue of Abbvie during FY 2020. This region’s revenue fell from $0.81 billion in FY 2019 to $0.41 billion in FY 2020.
• China: China contributed about 3% of Abbvie’s total revenue during FY 2020. The company did not earn any revenue from this region in FY 2019, while in FY 2020, it earned a revenue of $1.16 billion.
• France: This region contributed 1% of the total revenue in FY 2020. Its revenue fell from $0.69 billion in FY 2019 to $0.47 billion in FY 2020, which is a decrease of 32%.
• Brazil: Brazil contributed 1% of total revenue in FY 2020 amounting to $0.53 billion. There was a 47% increase in revenue compared to FY 2019 where the revenue generated was $0.36 billion.
• Japan: Despite being considered the economic powerhouse of Asia, the revenues for Abbvie products from Japan were lower than that from China during FY 2020. This region contributed 1% of the total revenue during FY 2020. The revenues from Japan during FY 2020 fell to $0.38 billion compared to FY 2019 when the revenue was $1.21 billion.
• Italy: During FY 2020, Italy contributed about 2% of the company’s total revenue. There was an increase in the company’s revenue from this region, from $0.37 billion in FY 2019 to $1.05 billion in FY 2020.
• Spain: This region contributed 3% of the total revenue in FY 2020. Its revenue grew from $0.47 billion in FY 2019 to $1.19 billion in FY 2020, which increase by 19%.
• The Netherlands: The Netherlands contributed 1% of total revenue in FY 2020 amounting to $0.45 billion. There was a 136% increase in revenue compared to FY 2019 where the revenue generated was $0.19 billion.
• United Kingdom: Despite being considered the economic powerhouse of Europe, the revenues for Abbvie products from the United Kingdom were lower than that from Spain during FY 2020. This region contributed 1% of the total revenue during FY 2020. The revenues from the United Kingdom during FY 2020 increased to $0.51 billion compared to FY 2019 when the revenue was $0.37 billion.
• Company Overview

Abbvie, a public limited company, originated due to a spin-off of Abbott Laboratories in 2013. It is headquartered in Lake Bluff, Illinois. They deal in Pharmaceutical drugs such as Humira, Skyrizi, Imbruvica, Venclexta, Zinbryta, Kaletra, Norvir, and Mavyret. Abbvie Inc’s key managerial persons are Richard A. Gonzalez(Chairman and CEO), and Michael Severino(Vice Chairman and President). As of 2020, the number of employees of the company worldwide was 47,000.  The competitors of Abbvie are Johnson & Johnson, Roche, Merck and Pfizer. The common stocks of Abbvie are listed on the New York Stock Exchange under the trading symbol “ABBV”.

Did you like Abbvie’s Revenue by Region statistic?

Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.

You can also get started for free.